Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty

Cancer
Emili Montserrat, Robert Peter Gale

Abstract

Because chronic lymphocytic leukemia is a heterogeneous disease, there are considerable efforts underway to develop increasingly accurate and precise analytics with which to estimate the probability of future events such as the need for and probability of response to therapy, progression-free survival, and survival. These analytics typically are constructed from clinical and laboratory variables. These variables often are combined into scores or staging systems, some of which are prognostic (therapy-independent), whereas others are predictive (therapy-dependent). Predictive variables differ with different therapies. Because response to therapy is a necessary condition for the improvement of survival, predictive biomarkers are extremely important. However, despite some progress to identify new predictive biomarkers, del(17p)/TP53 mutation remains the only widely accepted variable used to guide therapy. New laboratory techniques and analytical tools may contribute to improvements in the precision and accuracy of outcome indicators. However, there are inherent limitations when applying cohort-based estimates to individuals within the cohort. The accuracy and precision of prediction also are limited by measurement error and chance....Continue Reading

References

Sep 1, 1975·The American Journal of Medicine·L C PetersonR D Brunning
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emili Montserrat
Jun 1, 2010·Haematologica·David OscierUNKNOWN Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
May 2, 2013·Haematologica·Robin FoàGianluca Gaidano
Jun 28, 2013·The New England Journal of Medicine·Alexander K SmithRobert M Arnold
Oct 31, 2013·The American Journal of Gastroenterology·Amit G SingalAkbar K Waljee
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jun 20, 2014·Leukemia·P BaliakasUNKNOWN European Research Initiative on CLL (ERIC)
May 28, 2015·The New England Journal of Medicine·J Larry Jameson, Dan L Longo
Mar 2, 2016·Haematologica·Sarka PospisilovaUNKNOWN European Research Initiative on CLL (ERIC)
Aug 25, 2016·The New England Journal of Medicine·David J Hunter
Oct 16, 2016·Best Practice & Research. Clinical Haematology·Emili MontserratJulio Delgado
Nov 3, 2016·The New England Journal of Medicine·Arabella L Simpkin, Richard M Schwartzstein
Jan 20, 2017·Nature Reviews. Disease Primers·Thomas J KippsKanti Rai
Mar 23, 2017·Social Science & Medicine·Marij A HillenPaul K J Han
Apr 19, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A WoyachJohn C Byrd
Oct 7, 2017·Frontiers in Cell and Developmental Biology·Izumi V HinksonWarren A Kibbe
Oct 14, 2017·Blood·Chatree Chai-Adisaksopha, Jennifer R Brown
Mar 22, 2018·The New England Journal of Medicine·John F SeymourArnon P Kater
Apr 21, 2018·Nature Reviews. Clinical Oncology·Jonathan Kimmelman, Ian Tannock

❮ Previous
Next ❯

Citations

Jan 14, 2021·Expert Review of Hematology·Stefano Molica
May 1, 2021·Cancers·Isabel González-Gascón-Y-MarínJosé-Ángel Hernández-Rivas
Oct 2, 2021·Hematological Oncology·Stefano MolicaAaron Polliack

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

The Clinical Biochemist. Reviews
Graham H White
Current Opinion in Allergy and Clinical Immunology
Louis-Philippe Boulet, Pascal Chanez
Bulletin du cancer
Suzette DelalogeIntergroupe national de recherche sur le cancer du sein Unicancer (UCBG)
© 2021 Meta ULC. All rights reserved